These promising clinical activities have led to the further clinical evaluation of this peptide cancer vaccine platform as monotherapy or combination therapy with cyclophosphamide/radiation/IDO1 inhibitor in patients with HER2‐ breast cancer (phase 1, NCT04895761), ovarian, peritoneal carcinoma, or fallopian tube cancer (phase 1/2, NCT02785250; NCT03029403; phase 1, NCT03332576; phase 2, NCT05243524), hepatocellular carcinoma, NSCLC, bladder cancer (phase 2, NCT03836352), large B cell lymphoma (phase 2, NCT03349450 and NCT04920617). Here, ERBB2 is linked to cancer.